NasdaqGM - Nasdaq Real Time Price USD

Merus N.V. (MRUS)

40.45 +0.64 (+1.61%)
At close: April 22 at 4:00 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. Sven Ante Lundberg M.D. CEO, President & Executive Director 1.11M -- 1963
Mr. Gregory D. Perry Chief Financial Officer 419.1k -- 1960
Mr. Peter B. Silverman J.D. EVP, Company Secretary, COO, General Counsel, Chief Intellectual Property Officer & Head of US Legal 781.84k 565.02k 1978
Dr. Hui Liu Ph.D. Chief Business Officer, Executive VP & Head of Merus U.S. 640.14k 1.8M 1967
Dr. Andrew Joe M.D. Chief Medical Officer & Senior VP 685.12k -- 1967
Dr. Hennie Hoogenboom Co-Founder and Scientific Advisor -- -- --
Harry Shuman Chief Accounting Officer -- -- --
Mr. Cornelis Adriaan de Kruif Ph.D. CTO & Executive VP 345.21k -- 1965
Dr. Cecilia Anna Wilhelmina Geuijen Ph.D. Chief Scientific Officer & Senior VP -- -- --
Kathleen Farren IR & Corporate Communications Officer -- -- --

Merus N.V.

Uppsalalaan 17
3rd & 4th floor
Utrecht, 3584 CT
Netherlands
31 30 253 8800 https://www.merus.nl
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
172

Description

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

Corporate Governance

Merus N.V.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 02, 2024 - May 06, 2024
Merus N.V. Earnings Call

Related Tickers

SNDX Syndax Pharmaceuticals, Inc.
20.96
+0.77%
 
CRNX Crinetics Pharmaceuticals, Inc.
43.44
+1.09%
 
IDYA IDEAYA Biosciences, Inc.
37.59
+1.24%
 
KYMR Kymera Therapeutics, Inc.
34.35
+1.12%
 
MLTX MoonLake Immunotherapeutics
41.02
-2.77%
 
RVMD Revolution Medicines, Inc.
36.43
+4.32%
 
DYN Dyne Therapeutics, Inc.
24.87
+4.23%
 
KRYS Krystal Biotech, Inc.
157.25
-0.81%
 
IMCR Immunocore Holdings plc
55.82
+0.25%
 
NUVL Nuvalent, Inc.
64.49
+2.76%